Nimble Therapeutics announced their strategic research collaboration with Incyte has been expanded to include discovery of additional novel peptide therapies. Under the terms of the agreement, Nimble will receive an upfront payment and reimbursement of certain research program costs and may become eligible for downstream milestone payments and royalties. Incyte has exclusive rights to develop and commercialize any peptides discovered under the collaboration and has an option to further expand the collaboration to include additional targets.